Comparative Pharmacology
Head-to-head clinical analysis: MD 76 versus OXILAN 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 76 versus OXILAN 300.
MD-76 vs OXILAN-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-76 is a contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast between vascular structures and surrounding tissues. It distributes in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Iodinated contrast agent that attenuates X-rays and enhances vascular and tissue visualization during imaging procedures.
IV: 50-100 mL per dose, administered as a bolus or infusion, not to exceed 3 mL/kg total dose.
Intravenous: 1-2 mL/kg (300 mg iodine/mL) for contrast imaging; maximum dose 2 mL/kg per procedure.
None Documented
None Documented
Terminal half-life: 1.5–2 hours; prolonged in renal impairment (up to 20 hours in anuria); clinical context: allows rapid elimination, suitable for diagnostic imaging
Terminal half-life: 1.5–2.5 hours (normal renal function); prolonged in renal impairment (up to 30 hours in severe impairment).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Renal elimination: 100% unchanged via glomerular filtration; biliary/fecal excretion negligible (<1%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent